Vietnam Investment Review on MSN
GenEditBio gets FDA clearance for in vivo genome editing programme
The clearance allows human trials for its one-time treatment targeting a genetic eye disease that causes vision loss.
The US Food and Drug Administration (FDA) has cleared GenEditBio Limited’s Investigational New Drug (IND) application to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback